Atypical antipsychotic-like effects of the dopamine D3 receptor agonist, (+)-PD 128,907. 1998

J Witkin, and M Gasior, and J Acri, and M Beekman, and A Thurkauf, and J Yuan, and P DeBoer, and H Wikström, and D Dijkstra
Drug Development Group, NIDA Addiction Research Center, NIH, Baltimore, MD 21224, USA. jwitkin@irp.nida.nih.gov

Anti-schizophrenia agents with improved efficacy and side-effect profiles are required. A dopamine D3 receptor agonist, R-(+)-trans-3,4a,10b-tetrahydro-4-propyl-2H,5H-[1]benzopyrano[4,3- b]-1,4-oxazin-9-ol HCl ((+)-PD 128,907), displayed an atypical antipsychotic profile comparable to that of clozapine. (+)-PD 128,907 blocked stereotypy produced by dizocilpine (MK-801) at 12-fold lower doses than those affecting apomorphine-induced stereotypes in mice and did not produce catalepsy. These effects of (+)-PD 128,907 were stereospecific and were blocked by a D3 antagonist. These data suggest a role for D3 receptors in antipsychotic drug action.

UI MeSH Term Description Entries
D010078 Oxazines Six-membered heterocycles containing an oxygen and a nitrogen.
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001578 Benzopyrans Compounds with a core of fused benzo-pyran rings. Benzopyran,Chromene,Chromenes
D013239 Stereotyped Behavior Relatively invariant mode of behavior elicited or determined by a particular situation; may be verbal, postural, or expressive. Behavior, Stereotyped,Behaviors, Stereotyped,Stereotyped Behaviors
D014150 Antipsychotic Agents Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. Antipsychotic,Antipsychotic Agent,Antipsychotic Drug,Antipsychotic Medication,Major Tranquilizer,Neuroleptic,Neuroleptic Agent,Neuroleptic Drug,Neuroleptics,Tranquilizing Agents, Major,Antipsychotic Drugs,Antipsychotic Effect,Antipsychotic Effects,Antipsychotics,Major Tranquilizers,Neuroleptic Agents,Neuroleptic Drugs,Tranquillizing Agents, Major,Agent, Antipsychotic,Agent, Neuroleptic,Drug, Antipsychotic,Drug, Neuroleptic,Effect, Antipsychotic,Major Tranquilizing Agents,Major Tranquillizing Agents,Medication, Antipsychotic,Tranquilizer, Major
D017448 Receptors, Dopamine D2 A subfamily of G-PROTEIN-COUPLED RECEPTORS that bind the neurotransmitter DOPAMINE and modulate its effects. D2-class receptor genes contain INTRONS, and the receptors inhibit ADENYLYL CYCLASES. Dopamine D2 Receptors,Dopamine-D2 Receptor,D2 Receptors, Dopamine,Dopamine D2 Receptor,Receptor, Dopamine-D2
D050637 Receptors, Dopamine D3 A subtype of dopamine D2 receptors that are highly expressed in the LIMBIC SYSTEM of the brain. Dopamine D3 Receptors,Dopamine D3 Receptor,Dopamine Receptor D3,Receptor, Dopamine-D3,Dopamine-D3 Receptor
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus
D018491 Dopamine Agonists Drugs that bind to and activate dopamine receptors. Dopamine Receptor Agonists,Dopaminergic Agonists,Agonists, Dopamine Receptor,Agonists, Dopaminergic,Dopamine Agonist,Dopamine Receptor Agonist,Dopaminergic Agonist,Receptor Agonists, Dopamine,Agonist, Dopamine,Agonist, Dopamine Receptor,Agonist, Dopaminergic,Agonists, Dopamine,Receptor Agonist, Dopamine

Related Publications

J Witkin, and M Gasior, and J Acri, and M Beekman, and A Thurkauf, and J Yuan, and P DeBoer, and H Wikström, and D Dijkstra
September 2001, Neuropharmacology,
J Witkin, and M Gasior, and J Acri, and M Beekman, and A Thurkauf, and J Yuan, and P DeBoer, and H Wikström, and D Dijkstra
December 2017, Pharmacological reports : PR,
J Witkin, and M Gasior, and J Acri, and M Beekman, and A Thurkauf, and J Yuan, and P DeBoer, and H Wikström, and D Dijkstra
November 2011, Neurochemistry international,
J Witkin, and M Gasior, and J Acri, and M Beekman, and A Thurkauf, and J Yuan, and P DeBoer, and H Wikström, and D Dijkstra
December 1997, Journal of neurochemistry,
J Witkin, and M Gasior, and J Acri, and M Beekman, and A Thurkauf, and J Yuan, and P DeBoer, and H Wikström, and D Dijkstra
December 1996, Psychopharmacology,
J Witkin, and M Gasior, and J Acri, and M Beekman, and A Thurkauf, and J Yuan, and P DeBoer, and H Wikström, and D Dijkstra
August 2023, Psychopharmacology,
J Witkin, and M Gasior, and J Acri, and M Beekman, and A Thurkauf, and J Yuan, and P DeBoer, and H Wikström, and D Dijkstra
June 1998, Neuropharmacology,
J Witkin, and M Gasior, and J Acri, and M Beekman, and A Thurkauf, and J Yuan, and P DeBoer, and H Wikström, and D Dijkstra
August 2009, European journal of pharmacology,
J Witkin, and M Gasior, and J Acri, and M Beekman, and A Thurkauf, and J Yuan, and P DeBoer, and H Wikström, and D Dijkstra
January 2004, Polish journal of pharmacology,
J Witkin, and M Gasior, and J Acri, and M Beekman, and A Thurkauf, and J Yuan, and P DeBoer, and H Wikström, and D Dijkstra
May 2016, Behavioural brain research,
Copied contents to your clipboard!